Improved rescue of immature oocytes obtained from conventional gonadotropin stimulation cycles via human induced pluripotent stem cell-derived ovarian support cell co-culture

Alexa Giovannini, Sabrina Piechota, Maria Marchante, Kathryn Potts, Graham Rockwell, Bruna Paulsen, Alexander D Noblett, Samantha L. Estevez, Alexandra B Figueroa, Caroline Aschenberger, Dawn A. Kelk, Marcy Forti, Shelby Marcinyshyn, Ferran Barrachina, Klaus Wiemer, Marta Sanchez, Pedro Belchin, Merrick Pierson Smela, Patrick R.j. Fortuna, Pranam Chatterjee, David H. McCulloh, Alan B. Copperman, Daniel Ordonez-Perez, Joshua U. Klein, Christian KrammebioRxiv 2023 · DOI

TL;DR

This study introduces a novel method for improving the success rate of in vitro maturation (IVM) of immature human oocytes by co-culturing them with lab-grown ovarian support cells (OSCs) derived from induced pluripotent stem cells (hiPSCs). This approach significantly boosts the number of mature oocytes, yielding results comparable to naturally matured oocytes in terms of transcriptomic profile and spindle assembly, offering a promising advancement for fertility treatments.

What Problem Does This Paper Address?

In conventional fertility treatments like IVF, many retrieved oocytes are immature and often discarded, limiting the number of viable oocytes available for fertilization and embryo development. This is particularly problematic for patients with diminished ovarian reserve or those undergoing treatments where oocyte quality is paramount. While in vitro maturation (IVM) techniques exist to mature these immature oocytes, their effectiveness, especially for denuded oocytes (those stripped of their surrounding cumulus cells), has been limited, often resulting in oocytes with suboptimal nuclear and cytoplasmic maturity. This paper addresses the challenge of improving the efficiency and quality of IVM for these discarded immature oocytes, aiming to maximize the yield of usable oocytes for fertility treatments.

Methods

The core innovation in this study is the use of human induced pluripotent stem cell (hiPSC)-derived ovarian support cells (OSCs) in a co-culture system for in vitro maturation (IVM). These OSCs, engineered to mimic natural granulosa cells, were cultured with immature human oocytes (germinal vesicle or metaphase I stage) for 24-28 hours. The researchers compared this "OSC-IVM" approach to a standard "Media-IVM" control, which used the same maturation media but without the OSCs. Key assessments included:

  • Maturation Rate: Quantifying the percentage of oocytes that reached the metaphase II (MII) stage.
  • Morphological Quality: Evaluating oocyte quality using the Total Oocyte Score (TOS) system.
  • Spindle Assembly: Examining the presence and position of the meiotic spindle, a crucial indicator of oocyte quality.
  • Transcriptomic Profiling: Analyzing gene expression patterns of the matured oocytes using single-cell RNA sequencing to compare their molecular profiles to naturally matured oocytes.

Datasets

The study utilized immature oocytes donated by 47 fertility patients undergoing conventional ovarian stimulation at Extend Fertility New York and Ruber Clinic Madrid. Additionally, 34 metaphase II (MII) oocytes from conventional controlled ovarian stimulation (COS) were used as reference controls for transcriptomic analysis. These oocytes were obtained under informed consent and ethical approval.

Key Insights and Ideas

  • Stem Cells as Ovarian Support: The study demonstrates that hiPSC-derived OSCs can effectively mimic the supportive role of natural granulosa cells, significantly enhancing oocyte maturation.
  • Bridging the Gap for Denuded Oocytes: This method offers a viable solution for maturing denuded immature oocytes, which are often discarded in standard IVF protocols due to the removal of cumulus cells.
  • Transcriptomic Similarity to Natural Oocytes: A key finding is that OSC-IVM matured oocytes exhibit a transcriptomic profile remarkably similar to oocytes matured in vivo (IVF-MII controls), suggesting a higher degree of cytoplasmic and nuclear maturity compared to standard IVM.
  • Improved Spindle Assembly: OSC-IVM treatment resulted in MII oocytes with no instances of spindle absence, a critical factor for successful fertilization and development.

Key Results

  • Maturation Rate Boost: The OSC-IVM group showed a significantly higher oocyte maturation rate (62% ± 5.57% SEM) compared to the Media-IVM control (37% ± 8.96% SEM), representing a ~1.7X improvement.
  • Comparable Morphological Quality: While maturation rates improved, the morphological quality of MII oocytes (assessed by Total Oocyte Score) did not differ significantly between OSC-IVM and Media-IVM groups.
  • High Transcriptomic Similarity: OSC-IVM treated MII oocytes showed a transcriptomic signature significantly more similar to in vivo matured IVF-MII controls than those matured in Media-IVM.
  • Reduced Spindle Absence: Notably, MII oocytes derived from OSC-IVM had no instances of spindle absence, a positive indicator of oocyte quality.

Limitations and Future Work

The authors acknowledge that the study was limited by the number of subjects and oocytes utilized. Future research is needed to:

  • Elucidate Mechanisms: Further investigate the precise mechanisms by which OSCs enhance IVM outcomes.
  • Assess Embryo Development: Evaluate the embryo formation capacity and epigenetic health of oocytes matured using OSC-IVM.
  • Clinical Translation: Determine if embryos derived from OSC-IVM oocytes can achieve healthy implantation, development, and live birth compared to traditional IVM and IVF controls.
  • Standardization: The use of hiPSC-derived OSCs from a single source offers a novel approach for reproducible and standardized delivery of ovarian support cell co-culture, which is a key consideration for clinical application.

Summary updated

Abstract

Structured Abstract Purpose To determine if rescue in vitro maturation (IVM) of human oocytes can be improved by co-culture with ovarian support cells (OSCs) derived from human induced pluripotent stem cells (hiPSCs). Methods Fertility patients undergoing conventional ovarian stimulation for oocyte cryopreservation or IVF donated denuded immature germinal vesicle (GV) and metaphase I (MI) oocytes for research, which were allocated between either the control or intervention cultures. Fertility patients aged 25 to 45 years old donated immature oocytes under informed consent, with no additional inclusion criteria. The 24-28 hour OSC-IVM culture condition was composed of 100,000 OSCs in suspension culture with human chorionic gonadotropin (hCG), recombinant follicle stimulating hormone (rFSH), androstenedione and doxycycline supplementation. The Media-IVM control lacked OSCs and contained the same supplementation. Primary endpoints consisted of MII formation rate and morphological quality assessment. Additionally, metaphase spindle assembly location and oocyte transcriptomic profiles were assessed compared to in vivo matured MII oocyte controls. Results We observed significant improvement in maturation outcome rates (∼1.7X) for oocytes that underwent IVM with OSCs. Specifically, the OSC-IVM group yielded a maturation rate of 62% ± 5.57% SEM versus 37% ± 8.96% SEM in the Media-IVM ( p =0.0138, unpaired t- test). Oocyte morphological quality between OSC-IVM and the Media-IVM control did not significantly differ. OSC-IVM resulted in MII oocytes with no instances of spindle absence and no significant difference in position compared to in vivo matured IVF-MII controls. OSC-IVM treated MII oocytes display a transcriptomic signature significantly more similar to IVF-MII controls than the Media-IVM control MII oocytes did. Conclusion The novel OSC-IVM platform is an effective tool for rescue maturation of human oocytes obtained from conventional stimulation cycles, yielding oocytes with improved nuclear and cytoplasmic maturation. OSC-IVM shows broad utility for application in modern fertility treatment to improve the total number of available mature oocytes for fertility treatment.
BibTeX
@misc{giovannini2023improved,
  author = {Alexa Giovannini and Sabrina Piechota and Maria Marchante and Kathryn Potts and Graham Rockwell and Bruna Paulsen and Alexander D Noblett and Samantha L. Estevez and Alexandra B Figueroa and Caroline Aschenberger and Dawn A. Kelk and Marcy Forti and Shelby Marcinyshyn and Ferran Barrachina and Klaus Wiemer and Marta Sanchez and Pedro Belchin and Merrick Pierson Smela and Patrick R.J. Fortuna and Pranam Chatterjee and David H. McCulloh and Alan B. Copperman and Daniel Ordonez-Perez and Joshua U. Klein and Christian Kramme},
  title = {{Improved rescue of immature oocytes obtained from conventional gonadotropin stimulation cycles via human induced pluripotent stem cell-derived ovarian support cell co-culture}},
  year = {2023},
  doi = {10.1101/2023.03.27.534477},
  howpublished = {bioRxiv},
}
Figure